CVS Health Corporation $CVS Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D cut its stake in CVS Health Corporation (NYSE:CVS) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 434,295 shares of the pharmacy operator’s stock after selling 7,291 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in CVS Health were worth $34,466,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd raised its stake in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares during the period. Ares Financial Consulting LLC acquired a new position in shares of CVS Health during the 4th quarter worth approximately $29,000. Corundum Trust Company INC acquired a new position in shares of CVS Health during the 3rd quarter worth approximately $29,000. GoalVest Advisory LLC acquired a new position in shares of CVS Health during the 4th quarter worth approximately $32,000. Finally, SOA Wealth Advisors LLC. raised its stake in shares of CVS Health by 36.9% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after buying an additional 131 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Down 0.6%

Shares of CVS opened at $83.44 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. CVS Health Corporation has a one year low of $58.35 and a one year high of $85.15. The stock has a market capitalization of $106.93 billion, a price-to-earnings ratio of 60.46, a PEG ratio of 0.88 and a beta of 0.51. The stock has a 50 day moving average price of $76.32 and a 200 day moving average price of $77.97.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. During the same period in the previous year, the business earned $1.19 earnings per share. The firm’s revenue for the quarter was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts forecast that CVS Health Corporation will post 7.14 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.2%. The ex-dividend date is Thursday, April 23rd. CVS Health’s dividend payout ratio is presently 192.75%.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS won enterprise- and customer-facing AI awards, highlighting scaled AI deployments that could improve customer experience and operational efficiency. CVS Health’s Award Winning AI Raises Questions For Investors To Watch
• Positive Sentiment: CVS launched an AI health platform in partnership with Google Cloud, a strategic move that can accelerate digital services and pharmacy/clinic integration. CVS launches AI health platform with Google Cloud partnership
• Positive Sentiment: Barron’s published a bullish take arguing CVS is no longer a “value trap,” which can support investor sentiment and longer-term positioning despite near-term noise. CVS Earnings Are Coming. Why the Stock Is No Longer a Value Trap.
• Positive Sentiment: Steve Nelson, President of Aetna (a CVS company), was named to Health Catalyst’s board — a sign of CVS leadership visibility in health-tech partnerships and ecosystem influence. Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors
• Neutral Sentiment: Cigna’s exit from the ACA market and stronger-than-expected outlook for 2026 is industry news that could change exchange dynamics and PBM volumes — relevant but indirect for CVS. Cigna Exits Obamacare Market As PBM Profit Drops 28%
• Neutral Sentiment: Coverage of Viatris’s upcoming results and beat probability is being circulated (industry context for pharma supply/competitive backdrop). Viatris (VTRS) Earnings Expected to Grow: Should You Buy?
• Neutral Sentiment: Zacks and other sites note heightened investor interest/searches in CVS, which often precedes volatility around earnings and newsflow. Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
• Negative Sentiment: Analyst previews from Zacks/Yahoo warn CVS may report a decline in earnings and lack the key setup for an earnings beat; that caution pressures the stock ahead of results. Analysts Estimate CVS Health (CVS) to Report a Decline in Earnings: What to Look Out for
• Negative Sentiment: A Zacks Q1 preview highlights benefits pressure and elevated costs — noting health services growth may offset but not fully eliminate margin risk this quarter. CVS Q1 Earnings Preview: Health Services Likely to Lead Performance

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. The Goldman Sachs Group upped their target price on CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Robert W. Baird upped their target price on CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Wolfe Research reduced their target price on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Sanford C. Bernstein upgraded CVS Health from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $91.00 to $94.00 in a research report on Thursday, March 12th. Finally, Piper Sandler dropped their price target on CVS Health from $101.00 to $99.00 and set an “overweight” rating for the company in a research report on Tuesday, March 31st. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus target price of $95.05.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.